MAA Update on Mestinon Supply – 2 December 2022
The MAA continues to stay abreast of the Mestinon supply shortage issue and is in regular contact with government and industry stakeholders. The latest update for Timespan (180mg) and 60mg is below.
- Timespan (180mg): Section 19A approval is extended to 31 May 2023 (previously approved until 30 November 2022) and this is listed for subsidy under the PBS. This means you should pay what you normally pay for your Mestinon Timespan script. Medsurge Healthcare is currently assisting with the import and supply of this product. Please get your scripts in so that your Timespan can be ordered.
- 60mg: Section 19A approval has now been confirmed to 31 May 2023, however the PBS subsidy is not yet confirmed but we understand an application is pending. iNova Pharmaceuticals is currently assisting with the import and supply of this product.
A reminder that Section 19A aims to reduce the impact of the shortages of the usual Mestinon products brought into Australia.
Please ensure you take information provided by the MAA updates with you to your pharmacist to assist with the process.
Thank you for continuing to support each other as a patient community and if you have any concerns or feedback please contact us:
Email email@example.com or call (02) 4283 2815
Email firstname.lastname@example.org or call 1800 802 568